about
Direct oral anticoagulants: efficacy and safety in patient subgroupsDirect oral anticoagulants: a guide for daily practiceBiological effects of aspirin and clopidogrel in a randomized cross-over study in 96 healthy volunteersPlasma levels of the growth arrest-specific gene 6 product (Gas6) and antiplatelet drug responsiveness in healthy subjectsAssessing aspirin responsiveness using the Verify Now Aspirin assayVascular risk levels affect the predictive value of platelet reactivity for the occurrence of MACE in patients on clopidogrel. Systematic review and meta-analysis of individual patient data.Suspicion of heparin-induced thrombocytopenia in internal medicine: How appropriate is the ordering of anti-PF4/heparin antibody testing?Pannexin- and Connexin-Mediated Intercellular Communication in Platelet Function.Use of the PFA-100 closure time to predict cardiovascular events in aspirin-treated cardiovascular patients: a systematic review and meta-analysis.Intercellular communication in atherosclerosis.Clinical implications of clopidogrel non-response in cardiovascular patients: a systematic review and meta-analysis.Poor responsiveness to antiplatelet drugs in acute coronary syndromes: clinical relevance and management.Influence of the paraoxonase-1 Q192R genetic variant on clopidogrel responsiveness and recurrent cardiovascular events: a systematic review and meta-analysis.Thrombotic complications of myeloproliferative neoplasms: risk assessment and risk-guided management.Antiplatelet therapy: targeting the TxA2 pathway.Fibrinogen geneva II: a new congenitally abnormal fibrinogen alpha chain (Gly17Asp) with a review of similar mutations resulting in abnormal knob A.Direct oral anticoagulants in the treatment and long-term prevention of venous thrombo-embolism.How to manage prasugrel and ticagrelor in daily practice.Antiplatelet drug response status does not predict recurrent ischemic events in stable cardiovascular patients: results of the Antiplatelet Drug Resistances and Ischemic Events study.Pharmacogenomics of Oral Antithrombotic Drugs.Rivaroxaban-Induced Hemorrhage Associated with ABCB1 Genetic Defect.Management of direct oral anticoagulants in patients undergoing elective surgeries and invasive procedures: Updated guidelines from the French Working Group on Perioperative Hemostasis (GIHP) - September 2015.Genetic testing to identify women at risk of venous thromboembolism with contraceptive pills: Evidence or hope-based tool ?New molecular insights into modulation of platelet reactivity in aspirin-treated patients using a network-based approach.Impact of a product-specific reference standard for the measurement of a PEGylated rFVIII activity: the Swiss Multicentre Field Study.A multicenter study to assess the reproducibility of antiphospholipid antibody results produced by an automated system.Tailored Thienopyridine therapy: no urgency for CYP2C19 genotyping.PPM1A Methylation Is Associated With Vascular Recurrence in Aspirin-Treated Patients.Coadministration of ticagrelor and ritonavir: Toward prospective dose adjustment to maintain an optimal platelet inhibition using the PBPK approach.Impact of non-inhibited platelet supplementation on platelet reactivity in patients treated with prasugrel or ticagrelor for an acute coronary syndrome: An ex vivo study.The paraoxonase-1 pathway is not a major bioactivation pathway of clopidogrel in vitroClinical predictors of dual aspirin and clopidogrel poor responsiveness in stable cardiovascular patients from the ADRIE study.No influence of the VAMP8 rs1010 single nucleotide polymorphism on platelet functions in vitro.[Invasive procedures and long-term anti-coagulation: to bridge or not to bridge?].Adenosine diphosphate-induced platelet aggregation is associated with P2Y12 gene sequence variations in healthy subjects.P2Y12 H2 haplotype is associated with peripheral arterial disease: a case-control study.Subthalamic nucleus deep brain stimulation for Parkinson's disease in a patient with severe haemophilia A.[The concept of aspirin "resistance": mechanisms and clinical relevance].Connexin 37 limits thrombus propensity by downregulating platelet reactivity.Platelet hyperreactivity and dual antiplatelet therapy: can biases be avoided?
P50
Q27023677-61479234-A386-47E4-B3CE-F76CFAF7044CQ28071255-4F67EFF0-72DA-421A-9E8E-5C5BB07AC3C6Q28196714-3EDF5E25-D452-4F52-BBD3-60922A37BEA3Q28200541-2E2D4586-D2F1-4789-8DF3-2BA982E83169Q28212962-C408B600-CD67-41F0-A93A-CA3F9181F068Q31028203-33EC3D43-8B5E-47D8-9473-894192E56537Q33417957-D926103C-44D3-4D6E-AA2B-C9B96F94CF49Q33624852-4F9667BA-95AB-45C9-A1A6-B8080BB0D36FQ37056745-4A996105-B6FB-4A0C-8538-5C5B7E0AD81EQ37386451-55B62AA0-0300-4100-B06A-8ED639E29633Q37692536-F32B700B-FA22-46EA-909F-73C89BE49BAFQ37809122-535EDBEB-2881-4CC1-875A-D5201D2FA47FQ38004103-648F3B2E-3DD1-4B98-9860-694761459F4BQ38100371-B843B217-0DA2-4785-BBA3-84D3D36B2BD8Q38172461-701FE813-D96C-4BBE-9295-896913964C28Q38175777-6E2ABE2C-1574-4B4E-8740-2A9ADA1C9FD2Q38186641-9D5A4CC2-62A4-4578-9033-17A3F6FDB9A9Q38188201-0718310D-AC8F-4A3D-8EA4-787A633107B2Q38471154-F73D7050-6511-48BA-AF20-2417BA765671Q38661224-5519A130-523D-493E-A757-81E3C29F918FQ39032909-D87045A6-9189-49A0-A5EB-B3D7D762F99CQ39359988-B76EEAF7-C6C5-4567-922D-B492F5E3D423Q39653880-2DECFD1E-C482-47D5-97BA-CF9A6235B0A1Q39992304-1BACB70B-079E-43AA-9650-00161E818486Q40185654-DDA9D2F7-4C19-4713-A681-E12087702E5AQ40489485-FBC72336-0E4D-4CF5-A991-935957B86FF6Q40498149-FE59DFBF-E5D6-4A9D-933F-2C6E5DA162C1Q40701122-86AA17FA-EB5A-4200-97C0-0BD503CDDB93Q40717885-FC44E5E4-880E-4902-B78C-6C4C19D0D0D7Q41023511-ACA7E570-B214-42CF-9B9C-5AFC2F9DDE1CQ42326752-D88BB1C5-5AFA-4FE3-A9B2-323480022495Q42879719-6C473B80-355F-43AE-A4EA-4290EE545BD2Q42915064-A308D1A8-C4BA-449E-9E03-D94C02483A57Q44302173-1CE1044C-7817-4009-990D-19850B3123E9Q44545487-4B3A2C14-6AEC-4D43-B580-FC72E3F252DFQ44684860-757A40EE-0CFB-41BF-870F-D028C3768682Q45867841-DA5DC46E-A4C7-4933-8079-7EF42BCB782AQ45930919-4A884E11-17D0-48A0-8D0C-4857114C461EQ45990622-B992A9B5-99C9-44DD-B1FE-452433595722Q46226945-A5B9A9A8-55FF-4A8E-B080-345920D97DCC
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Pierre Fontana
@ast
Pierre Fontana
@en
Pierre Fontana
@es
Pierre Fontana
@nl
Pierre Fontana
@sl
type
label
Pierre Fontana
@ast
Pierre Fontana
@en
Pierre Fontana
@es
Pierre Fontana
@nl
Pierre Fontana
@sl
prefLabel
Pierre Fontana
@ast
Pierre Fontana
@en
Pierre Fontana
@es
Pierre Fontana
@nl
Pierre Fontana
@sl
P1053
M-3702-2014
P106
P21
P31
P3829
P496
0000-0003-1546-0774